ArticleJournal of health economics and outcomes research2021

Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors.

Xue Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.